ARA-290
Last updated: January 6, 2025
For informational purposes only. Not medical advice. Always consult a healthcare professional.
Tried ARA-290? Be part of the collective knowledge. Share your experience - your insights help others on their journey.
What Is ARA-290?
ARA-290 (cibinetide) is a synthetic peptide derived from erythropoietin (EPO) that selectively activates the innate repair receptor. It promotes tissue repair and has neuroprotective properties without the blood-building effects of EPO.
This is a peptide. Most peptides are research chemicals requiring reconstitution and subcutaneous injection. Purity and storage conditions matter.
ARA-290 Research & Studies
01 Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy ▸
Investigated safety and effectiveness of ARA 290 in reducing small fiber neuropathy symptoms in 22 sarcoidosis patients, showing significant symptom improvement.
View Study (Leiden University Medical Center)02 ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes ▸
Found ARA 290 improved blood sugar levels, lipid profiles, and reduced neuropathic pain in type 2 diabetes patients.
View Study (Araim Pharmaceuticals)03 Nonerythropoietic Erythropoietin Mimetic Peptide ARA290 Ameliorates Chronic Stress-Induced Depression-Like Behavior and Inflammation in Mice ▸
Demonstrated ARA290 reduces depression-like behavior in stressed mice similar to fluoxetine via anti-inflammatory effects.
View Study (Beijing Institute of Basic Medical Sciences)04 The erythropoietin analog ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain ▸
Reviews ARA 290 as promising treatment for sarcoidosis-induced debilitating neuropathic pain.
View Study (Leiden University Medical Center)05 ARA 290, a Peptide Derived from the Tertiary Structure of Erythropoietin, Produces Long-Term Relief of Neuropathic Pain ▸
Explored ARA290 effects on neuropathic pain in rats, finding dose-dependent pain reduction by decreasing inflammatory cell activity.
View Study (Leiden University Medical Center)06 ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury ▸
Found ARA290 improved kidney function and reduced tissue damage in pigs after induced kidney injury.
View Study (University of Groningen)ARA-290 User Reviews & Experiences
Sentiment score computed from aggregated public user reports, forums, and community discussions. Not a clinical measure.
Limited user reports, but those with neuropathy report significant symptom improvement. More commonly used in clinical settings than by individual biohackers.
ARA-290 Benefits, Dosage & Side Effects
- Neuropathy Relief: Primary use is for small fiber neuropathy and diabetic neuropathy.
- Tissue Repair: Promotes healing and repair of damaged tissues.
- Anti-Inflammatory: Reduces inflammatory markers without immunosuppression.
- Neuroprotective: May protect neurons from damage and promote regeneration.
- Clinical Evidence: Strong clinical trial data for neuropathy conditions.
- Targeted Action: Works specifically on tissue repair pathways.
- Clinical Dosing: 4mg subcutaneous injection, typically 3 times per week.
- Research Use: Dosing may vary in research contexts.
- Generally Well Tolerated: Few adverse effects reported in clinical trials.
- Injection Site Reactions: Minor irritation at injection site possible.
- Research Chemical: Primarily available through research chemical suppliers.
- Clinical Trials: Has been used in formal clinical trials.
- Specialized Sourcing: Not as widely available as other peptides.
Related Compounds
Community Reviews
Share your experience with ARA-290 and help others make informed decisions.
Write a Review
Sign in to leave a review